VIKAS SAYAL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
- Where
- BULLHEAD CITY, AZ
- NPI
- 1811109226
- Received
- $85,129 in 820 records, 2019 to 2025 ($84,942 general, $187 research)
- As principal investigator
- $3,589,618 of research payments to others in 602 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 125 | $3,006 |
| 2024 | General payment | 127 | $2,844 |
| 2024 | Research payment | 1 | $187 |
| 2023 | General payment | 186 | $26,904 |
| 2022 | General payment | 138 | $18,278 |
| 2021 | General payment | 120 | $21,394 |
| 2020 | General payment | 57 | $3,603 |
| 2019 | General payment | 66 | $8,911 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 36 | $65,190 |
| Food and Beverage | 764 | $18,188 |
| Travel and Lodging | 8 | $1,155 |
| Education | 11 | $408 |
| Research payment | 1 | $187 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-16 | Verona Pharma, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-16 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-15 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-12 | Baxter Healthcare | $20 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2025 | |
| 2025-12-11 | Electromed, Inc. | $10 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-12-11 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-12-04 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-11-19 | Electromed, Inc. | $5 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-11-19 | Electromed, Inc. | $3 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-11-17 | La Jolla Pharmaceutical Company | $16 | Education | In-kind items and services | ZEVTERA Drug, INFECTIOUS DISEASE | 2025 | |
| 2025-11-12 | Grifols USA, LLC | $23 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-11-10 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | Electromed, Inc. | $10 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-10-24 | GENZYME CORPORATION | $5 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-23 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-10-17 | Actelion Pharmaceuticals US, Inc. | $29 | Food and Beverage | In-kind items and services | OPSYNVI Drug, Pulmonary Hypertension | 2025 | |
| 2025-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23 | Food and Beverage (2 payments) | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-10-16 | JAZZ PHARMACEUTICALS INC. | $32 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-10-16 | Insmed, Inc. | $17 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-16 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-08 | Actelion Pharmaceuticals US, Inc. | $20 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-10-03 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-09-30 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-29 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-25 | Verona Pharma, Inc. | $19 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-09-25 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-19 | Baxter Healthcare | $28 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2025 | |
| 2025-09-16 | Electromed, Inc. | $9 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-09-16 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-09-08 | AstraZeneca Pharmaceuticals LP | $104 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-04 | JAZZ PHARMACEUTICALS INC. | $20 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-09-03 | Viatris Specialty LLC | $21 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-08-26 | Actelion Pharmaceuticals US, Inc. | $29 | Food and Beverage | In-kind items and services | OPSYNVI Drug, Pulmonary Hypertension | 2025 | |
| 2025-08-26 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-08-22 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-08-19 | Insmed, Inc. | $25 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-19 | Electromed, Inc. | $5 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-08-19 | Electromed, Inc. | $3 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-08-14 | Vifor Pharma, Inc. | $24 | Food and Beverage | In-kind items and services | Veltassa Drug, Nephrology | 2025 | |
| 2025-08-14 | INOGEN, INC. | $23 | Food and Beverage | Cash or cash equivalent | INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Device, OXYGEN CONCENTRATOR | 2025 | |
| 2025-08-12 | Verona Pharma, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-08 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-08 | Insmed, Inc. | $17 | Education | In-kind items and services | 2025 | ||
| 2025-08-06 | Regeneron Healthcare Solutions, Inc. | $130 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-04 | Actelion Pharmaceuticals US, Inc. | $21 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-07-31 | Baxter Healthcare | $28 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2025 | |
| 2025-07-28 | Regeneron Healthcare Solutions, Inc. | $94 | Education | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-16 | Electromed, Inc. | $14 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-07-16 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-07-03 | Verona Pharma, Inc. | $30 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-07-01 | Insmed, Inc. | $25 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-06-27 | Regeneron Healthcare Solutions, Inc. | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-27 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-06-25 | Electromed, Inc. | $7 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-06-25 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-25 | Electromed, Inc. | $3 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-06-25 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-06-16 | Amgen Inc. | $25 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-06-13 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-02 | Verona Pharma, Inc. | $30 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-30 | Vifor Pharma, Inc. | $27 | Food and Beverage | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-30 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-28 | GlaxoSmithKline, LLC. | $118 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-27 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-22 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-05-21 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-05-20 | Electromed, Inc. | $6 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-05-20 | Electromed, Inc. | $2 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-05-16 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-15 | Verona Pharma, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-05-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-05-07 | Electromed, Inc. | $10 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-05-07 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-05-02 | SANOFI-AVENTIS U.S. LLC | $78 | Education | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-02 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-29 | Vifor Pharma, Inc. | $25 | Food and Beverage | In-kind items and services | Veltassa Drug, Nephrology | 2025 | |
| 2025-04-25 | Baxter Healthcare | $24 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2025 | |
| 2025-04-19 | AstraZeneca Pharmaceuticals LP | $31 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-17 | Merck Sharp & Dohme LLC | $124 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-04-17 | Grifols USA, LLC | $27 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-04-08 | Electromed, Inc. | $13 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-04-08 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-04-04 | Merck Sharp & Dohme LLC | $28 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-04-02 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-04-02 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-04-01 | Verona Pharma, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-03-29 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-03-27 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-03-25 | Electromed, Inc. | $6 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-03-25 | Electromed, Inc. | $3 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-03-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-03-14 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-13 | Grifols USA, LLC | $27 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-03-07 | JAZZ PHARMACEUTICALS INC. | $38 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-03-05 | Electromed, Inc. | $8 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-03-05 | Electromed, Inc. | $4 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-02-27 | Baxter Healthcare | $28 | Food and Beverage | In-kind items and services | Hillrom - Volara System Device, Airway Clearance Device | 2025 | |
| 2025-02-25 | Grifols USA, LLC | $22 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-02-25 | Verona Pharma, Inc. | $18 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-02-20 | Takeda Pharmaceuticals U.S.A., Inc. | $23 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-02-19 | GlaxoSmithKline, LLC. | $25 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-02-17 | Viatris Specialty LLC | $21 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-02-13 | AstraZeneca Pharmaceuticals LP | $29 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-02-12 | Inspire Medical Systems, Inc. | $100 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-02-12 | Electromed, Inc. | $16 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-02-06 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-02-04 | GlaxoSmithKline, LLC. | $21 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-02-04 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-01-30 | Verona Pharma, Inc. | $21 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-01-29 | Viatris Specialty LLC | $22 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-01-27 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-23 | AstraZeneca Pharmaceuticals LP | $19 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-21 | Electromed, Inc. | $15 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-01-21 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-01-20 | Verona Pharma, Inc. | $25 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-01-18 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-01-16 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage (4 payments) | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-01-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-01-11 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-09 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2024-12-19 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-12-18 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-12-18 | Insmed, Inc. | $25 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2024 | |
| 2024-12-18 | Insmed, Inc. | $18 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2024 | |
| 2024-12-10 | Mylan Specialty L.P. | $20 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2024 | |
| 2024-12-09 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-12-09 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-12-09 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-12-04 | Electromed, Inc. | $16 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-12-04 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-12-03 | Intuitive Surgical, Inc. | $124 | Food and Beverage | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-12-03 | Intuitive Surgical, Inc. | $118 | Food and Beverage | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-11-23 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-11-21 | GlaxoSmithKline, LLC. | $32 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-11-19 | Inspire Medical Systems, Inc. | $85 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2024 | |
| 2024-11-19 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-11-19 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-11-19 | Philips North America LLC | $18 | Food and Beverage | Cash or cash equivalent | (8874) inCourage Device, Medical Device | 2024 | |
| 2024-11-19 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-11-15 | Grifols USA, LLC | $31 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2024 | |
| 2024-11-13 | Electromed, Inc. | $13 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-11-13 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-11-13 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-11-11 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-11-04 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-11-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-11-01 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-10-30 | Mylan Specialty L.P. | $23 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2024 | |
| 2024-10-30 | Electromed, Inc. | $17 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-10-28 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-10-28 | Electromed, Inc. | $8 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-10-17 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-10-17 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-10-11 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2024 | |
| 2024-10-11 | Inspire Medical Systems, Inc. | $19 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2024 | |
| 2024-10-10 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2024 | |
| 2024-10-08 | Merck Sharp & Dohme LLC | $25 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-10-08 | Merck Sharp & Dohme LLC | $10 | Education | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-10-08 | GlaxoSmithKline, LLC. | $1 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-10-04 | Regeneron Healthcare Solutions, Inc. | $38 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-10-04 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-09-27 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-09-26 | GlaxoSmithKline, LLC. | $26 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-09-25 | Grifols USA, LLC | $22 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2024 | |
| 2024-09-23 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-09-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-09-19 | Mylan Specialty L.P. | $32 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2024 | |
| 2024-09-12 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-09-09 | Electromed, Inc. | $11 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-09-05 | Merck Sharp & Dohme LLC | $26 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-09-04 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2024-08-29 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-08-20 | Electromed, Inc. | $15 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-08-20 | Electromed, Inc. | $0 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-08-15 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-08-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-08-05 | Merck Sharp & Dohme LLC | $25 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-08-05 | Merck Sharp & Dohme LLC | $10 | Education | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-08-01 | GENZYME CORPORATION | $34 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-07-29 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2024 | |
| 2024-07-29 | Electromed, Inc. | $17 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-07-29 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-07-26 | AstraZeneca Pharmaceuticals LP | $33 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2024 | |
| 2024-07-25 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-07-16 | Intuitive Surgical, Inc. | $85 | Food and Beverage | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-07-10 | Electromed, Inc. | $11 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-07-10 | Electromed, Inc. | $1 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-07-01 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2024 | |
| 2024-06-27 | Regeneron Healthcare Solutions, Inc. | $99 | Education | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-06-27 | Regeneron Healthcare Solutions, Inc. | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | 2024 | |
| 2024-06-26 | Electromed, Inc. | $11 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-06-26 | Electromed, Inc. | $10 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-06-24 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 |
The latest 200 records of 820.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $179 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $93 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $99 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $41 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $41 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $41 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $99 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $93 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $179 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $414 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $99 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $93 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $179 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-22 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $5,700 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody R | 2025 |
| 2025-12-19 | ModernaTX, Inc. | HENDERSON CLINICAL TRIALS LLC | $10,387 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $60 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $102 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $57 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | ModernaTX, Inc. | HENDERSON CLINICAL TRIALS LLC | $309 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | 2025 |
| 2025-12-19 | CSL Behring | HENDERSON CLINICAL TRIALS | $12,000 | A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evalu | 2025 |
| 2025-12-19 | ModernaTX, Inc. | HENDERSON CLINICAL TRIALS LLC | $46 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | 2025 |
| 2025-12-19 | CSL Behring | HENDERSON CLINICAL TRIALS | $2,000 | A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evalu | 2025 |
| 2025-12-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $3,194 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-17 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $10,000 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | 2025 |
| 2025-12-11 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,800 | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-12-08 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $1,483 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $6,700 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-12-08 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $750 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $6,385 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $207 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $102 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $57 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-26 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $60 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-24 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $2,439 | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in A | 2025 |
| 2025-11-24 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $320 | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | 2025 |
| 2025-11-24 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $244 | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | 2025 |
| 2025-11-24 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $189 | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | 2025 |
| 2025-11-24 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $2,482 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $199 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $1,337 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-12 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,800 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-11-12 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $19,322 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-11-12 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,200 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-11-12 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,000 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-11-04 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $3,366 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and T | 2025 |
| 2025-11-04 | PFIZER INC. | HENDERSON CLINICAL TRIALS LLC | $16,500 | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFET | 2025 |
| 2025-11-04 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $157 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $207 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $207 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $57 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $60 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $138 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $179 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $99 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $102 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $93 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $676 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $57 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $121 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-29 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $89 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-24 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $821 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-23 | ModernaTX, Inc. | HENDERSON CLINICAL TRIALS LLC | $4,177 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | 2025 |
| 2025-10-23 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,735 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $4,257 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $330 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 W | 2025 |
| 2025-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $1,900 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 W | 2025 |
| 2025-10-20 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $28 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $1,316 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $199 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-15 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $430 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $5,822 | A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $2,422 | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in A | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $22,628 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $1,950 | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2025 |
| 2025-10-07 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $270 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | 2025 |
| 2025-10-06 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $300 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody R | 2025 |
| 2025-10-06 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $20,900 | A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody R | 2025 |
| 2025-10-06 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $15,408 | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and saf | 2025 |
| 2025-10-01 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $7,130 | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 | 2025 |
| 2025-10-01 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $33,541 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 W | 2025 |
| 2025-10-01 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $400 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 W | 2025 |
| 2025-10-01 | Takeda Pharmaceuticals U.S.A., Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 W | 2025 |
| 2025-09-22 | SANOFI US SERVICES INC. | HENDERSON CLINICAL TRIALS LLC | $102 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and T | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $2,541 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $1,278 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-18 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $1,676 | A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $2,715 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $60 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-17 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $61 | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $110 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-17 | GlaxoSmithKline, LLC. | HENDERSON CLINICAL TRIALS LLC | $66 | A MULTICENTRE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDI | 2025 |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | HENDERSON CLINICAL TRIALS LLC | $179 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bullhead City, AZ, county Mohave County, AZ, state Arizona; placed by its city name.
| Measure | Place (city or town) Bullhead City, AZ | County Mohave County, AZ | State Arizona |
|---|---|---|---|
| Population B01003 | 42,496 | 220,517 | 7,378,838 |
| Population, 2020 census P1 | 41,348 | 213,267 | 7,151,502 |
| Median age B01002 | 56.0 | 53.6 | 39.0 |
| Under 18 B01001 | 14.5% | 16.1% | 21.6% |
| 65 and over B01001 | 34.3% | 32.6% | 18.9% |
| Households B11001 | 20,952 | 101,973 | 2,856,081 |
| Foreign born B05002 | 8.9% | 6.1% | 13.0% |
| Median household income B19013 | $50,556 | $57,684 | $79,964 |
| Median family income B19113 | $61,703 | $70,608 | $95,980 |
| Per capita income B19301 | $35,822 | $35,963 | $42,503 |
| Poverty rate B17001 | 18.7% | 16.1% | 12.5% |
| Unemployment rate B23025 | 11.5% | 7.3% | 5.1% |
| Civilian labor force B23025 | 16,364 | 83,988 | 3,598,840 |
| Mean commute (minutes) B08013 | 20.4 | 19.9 | 25.4 |
| Bachelor's degree or higher B15003 | 15.2% | 15.2% | 33.3% |
| Housing units B25001 | 25,220 | 121,881 | 3,192,839 |
| Owner-occupied B25003 | 69.9% | 74.1% | 67.4% |
| Renters B25003 | 30.1% | 25.9% | 32.6% |
| Median home value B25077 | $211,500 | $281,000 | $394,500 |
| Median gross rent B25064 | $1,079 | $1,091 | $1,543 |
| White, not Hispanic B03002 | 68.7% | 74.9% | 52.6% |
| Black B03002 | 1.6% | 1.0% | 4.4% |
| Hispanic or Latino B03002 | 22.8% | 17.1% | 31.4% |
| Asian B03002 | 1.5% | 1.1% | 3.5% |
| American Indian and Alaska Native B03002 | 0.5% | 1.3% | 3.2% |
Economy now FRED unemployment 4.9% in Sep 2026 (4.4% a year earlier); per capita personal income $68,373 in 2025, up 31% in five years (+5.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bullhead City, AZ.
Comments